SHANGHAI, July 20, 2021 / PRNewswire / – GenFleet Therapeutics, a clinical-stage biotechnology company specializing in advanced therapies in oncology and immunology, and Insilico Medicine, an industry leader in end-to-end artificial intelligence for target discovery, Small Molecule Chemistry and Development, announced to enter into a strategic partnership in advancing the development of new therapies today.
The agreement describes a constructive framework in which GenFleet will synergize its own R&D systems with Insilico’s AI-based end-to-end drug discovery platform, with the aim of jointly responding to important unmet medical needs and to tackle new and challenging targets in cancer therapy.
In collaboration with Insilico’s AI-based identification methods, GenFleet will enhance the exploration of the dynamic structure-activity relationship between target proteins and drug molecules through virtual structure research to develop highly inhibitors. selective and provide targeted therapies overcoming drug resistance.
Equipped with a competitive pipeline with novel mechanisms, GenFleet has established its full R&D functions ranging from early discovery to global multiregional clinical trials. By pursuing targets and indications without proof of concept on a global scale, GenFleet has applied the latest computer science to drug development, including DNA-encoded library screening, computer-aided drug design, drug solutions. digital clinical trials, etc.
Insilico Medicine is a global leader in drug discovery powered by AI. Since 2014, Insilico Medicine has developed the AI-based drug discovery platform comprising the AI-based novel target discovery engine PandaOmics ™, the Chemistry42 ™ deep generative reinforcement learning system enabling the design de novo new molecules with the desired properties that do not exist in the known chemical space and InClinico ™, which predicts the results of clinical trials. As a pioneer and industry leader, Insilico Medicine has built a strong drug discovery and development team, an extensive network of distributed discovery partners, and launched several in-house therapy programs.
“GenFleet’s portfolio strategy is heavily based on strong technical capabilities, and since its inception, GenFleet has leveraged these best-in-class capabilities around the world. Through the integration of conventional biotechnology approaches with emerging technologies such as AI and computational biology, we expect that our R&D capacity and efficiency will receive a tremendous boost through optimization. target screening, molecular design, real-world clinical research, among others. We are very excited to form a collaboration with leading companies like Insilico, and look forward to a “game changers,” said Qiang Lu, Ph.D., co-founder and chairman of the board of GenFleet Therapeutics.
“Through the cooperation, GenFleet will strengthen its R&D systems with the AI-powered platform and we expect to dramatically improve the success rate of designing original preclinical candidate compounds in a shortened cycle time. GenFleet will constantly use new tools and techniques to enrich its fit. cutting-edge pipeline and developing life-saving drugs for patients around the world, ”said Jiong lan, Ph.D., co-founder and CEO of GenFleet Therapeutics.
“At Insilico, we only partner with companies that are committed to innovating using the latest advancements in next-generation AI. We are very excited to partner with GenFleet, one of the most innovative biotech companies in the world. world. China is now working to unleash the power of world-class artificial intelligence systems to discover and develop cutting-edge therapies to benefit patients around the world, ”said Alex Zhavoronkov, PhD, Founder and CEO, Insilico Medicine.
“Embracing cooperation and innovation, Insilico is honored to form a partnership with GenFleet who shares with us the commitment to the development of innovative medicines. By analyzing and screening huge volumes of data, Insilico’s AI-powered platform features unique generation model management and reinforcement learning techniques. We believe that our collaboration will provide GenFleet with powerful assistance in its development of transformative therapies, ”said Feng ren, Ph.D., Scientific Director of Insilico Medicine.
About GenFleet Therapeutics
Dedicated to meeting important unmet medical needs, GenFleet Therapeutics builds its R&D platform on the basis of disease biology and translational medicine, and studies the latest biological mechanisms of cancer pathways, the tumor microenvironment and the human immunoregulation. GenFleet’s rich and diverse pipeline highlights several cutting-edge products with innovative mechanisms and global intellectual property rights.
Through years of effort, GenFleet has built up cutting-edge capabilities and expertise in the development of new drugs – both small molecules and biologics. Its state-of-the-art pipeline includes more than 10 products, three of which have entered the clinical stage. As more projects enter advanced clinical trials, GenFleet is expected to unveil its commercialization plan over the next 3-5 years.
About Insilico Medicine
Insilico Medicine, an end-to-end artificial intelligence-based drug discovery company, developing artificial intelligence platforms (www.insilico.com/platform/) that use deep generative models, reinforcement learning, the transformer and other modern machine learning techniques to further target the discovery and generation of new molecular structures with desired properties. It develops revolutionary solutions for the discovery and development of innovative drugs against cancer, fibrosis, infectious diseases, autoimmune diseases and diseases related to aging. Since 2014, Insilico Medicine has established strategic collaborations with more than 30 pharmaceutical and biotechnology companies and academic research groups in United States, Europe, China, Japan and other countries and regions, and has launched several internal R&D pipelines for new, difficult and previously inaccessible targets. He has also established a collaboration with Syngenta to develop and apply AI to sustainable agriculture. Since its inception, the company has raised more than $ 300 million from reputable investors in the fields of finance, biotechnology and information technology.
CONTACT: [email protected]
SOURCE Insilico Medicine